<DOC>
	<DOCNO>NCT02601703</DOCNO>
	<brief_summary>This Randomized , Double-Blind , Placebo-Controlled , Parallel-Group , Multiple-Site Study Evaluate Therapeutic Equivalence Generic Tacrolimus Ointment , 0.1 % ( Glenmark Pharmaceuticals , Ltd ) Marketed Product ProtopicÂ® ( tacrolimus ) ointment , 0.1 % ( Astellas Pharma US , Inc. ) Treatment Moderate Severe Atopic Dermatitis ( AD ) .</brief_summary>
	<brief_title>To Study Generic Tacrolimus Ointment , 0.1 % Treatment Moderate Severe Atopic Dermatitis ( Inflammation Skin : Itchy , Red , Swollen , Cracked Skin )</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Key 1 . Nonimmunocompromised male nonpregnant , nonlactating female , 18 year age old clinical diagnosis moderate severe AD . 2 . Have confirm diagnosis atopic dermatitis least 3 month use diagnostic feature describe Hanifin Rajka 3 . Have IGA score 3 ( moderate ) 4 ( severe ) . 4 . Have affect Body Surface Area ( BSA ) least 20 % baseline . 5 . Treated bland emollient least 7 day . Key 1 . Active cutaneous bacterial viral infection treatment area baseline . 2 . Sunburn , extensive scarring , pigment lesion ( ) treatment area baseline . 3 . History confound skin condition , e.g. , psoriasis , rosacea , erythroderma , ichthyosis . 4 . History presence Netherton 's Syndrome , immunological deficiency disease , HIV , diabetes , malignancy , serious active recurrent infection , clinically significant severe renal insufficiency severe hepatic disorder . 5 . Known allergy hypersensitivity tacrolimus component Study product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>